The use of tumor-derived extracellular vesicles to deliver therapeutic miRNAs was recently reported, wherein the authors described the efficient delivery of the tumor suppressive miRNA let-7a to epidermal growth factor receptor (EGFR)-expressing breast cancer cells in vivo. This evidence concerns the gene EGFR and neoplasm.